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Genetic factors in end-stage renal disease. Despite more aggres-
sive treatment of diabetes, hypertension, and hyperlipidemia,
the incidence and prevalence rates of end-stage renal disease
(ESRD) continue to increase worldwide. The likelihood of de-
veloping chronic kidney disease in an individual is determined
by interactions between genes and the environment. Familial
clustering of nephropathy has repeatedly been observed in all
population groups studied and for multiple etiologies of kidney
disease. A three- to nine-fold greater risk of ESRD is observed
in individuals with a family history of ESRD. Marked racial
variation in the familial aggregation of kidney disease exists,
with high rates in African American, Native American, and
Hispanic American families. Disparate etiologies of nephropa-
thy aggregate within African American families, as well. These
data have led several investigators to search for genes linked to
diabetic and other forms of nephropathy. Evidence for linkage
to kidney disease has been detected and replicated at several
loci on chromosomes 3q (types 1 and 2 diabetic nephropathy),
10q (diabetic and nondiabetic kidney disease), and 18q (type 2
diabetic nephropathy). Multicenter consortia are currently re-
cruiting large numbers of multiplex diabetic families with index
cases having nephropathy for linkage and association analyses.
In addition, large-scale screening studies are underway, with the
goals of better defining the overall prevalence of chronic kidney
disease, as well as educating the population about risk factors for
nephropathy, including family history. Given the overwhelming
burden of kidney disease worldwide, it is imperative that we de-
velop a clearer understanding of the pathogenesis of nephropa-
thy so that individuals at risk can be identified and treated at
earlier, potentially reversible, stages of their illness.
End-stage renal disease (ESRD) has reached epidemic
proportions, with more than 400,000 affected individuals
in the United States, and well over one million world-
wide. [1] These staggering numbers represent only the
tip of the iceberg, as the incidence of chronic kidney dis-
ease is at least 30-fold higher than that of ESRD [2, 3].
At the current rate of growth, it is expected that the in-
cidence rate of new ESRD cases in the U.S. will be over
400,000 per year in 2030, with an estimated prevalence
of over two million [1]. The economic impact of this is
staggering: the ESRD program in the U.S. in 2001 cost
$22.83 billion [1]. This cost estimate includes only direct
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health care expenditures, and excludes indirect costs such
as lost productivity. This has generated enormous interest
in identifying risk factors for kidney failure, in the hope
that earlier treatment can prevent ESRD from develop-
ing in susceptible individuals.
Enhanced susceptibility to chronic kidney disease can
be caused by environmental factors, genes, and their
interaction [4]. This review focuses on the association
between genetic factors and ESRD, allowing that a per-
missive environment (i.e., hyperglycemia or hyperten-
sion) is required for expression of genetic susceptibility.
RISK ASSOCIATED WITH FAMILY HISTORY
One of the most important risk factors for developing
chronic kidney disease in an individual is the presence of
a family history of ESRD. Several U.S. reports reveal a
three- to nine-fold greater risk of developing ESRD in
individuals with relatives having ESRD [5–7]. Significant
racial variation exists in susceptibility, with a high risk
attributable to family history in the African American
[8], Native American [9], and possibly Hispanic Ameri-
can [10] populations. In a case-control study from North
Carolina, our group reported that African Americans
with a first-degree relative on dialysis had a nine-fold
higher risk of developing ESRD than did age-, sex-,
and race-matched control subjects [6]. This association
was also observed in African Americans residing in Los
Angeles, where subjects with a history of chronic renal
failure in first- or second-degree relatives had a greater
than five-fold increased risk of ESRD compared with
race-matched controls [5]. Our group found that fam-
ily history also correlated with excess risk for ESRD in
Caucasian Americans, albeit to a lesser extent. In this
population, a three-fold higher risk was seen in individu-
als who had either first- or second-degree relatives with
ESRD [7]. While racial predilections are seen, explana-
tions for the racially variable susceptibility rates are not
yet clear. It is likely that the increased familial clustering
of chronic kidney disease in certain races is associated
with genetic and environmental factors.
One’s family history of ESRD is more predictive for
subsequent development of chronic kidney disease in a
hypertensive or diabetic individual than is the level of
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blood pressure or glucose control [8, 11] This is not to
suggest that control of modifiable factors such as hy-
pertension and hyperglycemia does not play an impor-
tant role in decreasing the likelihood of development
or progression of nephropathy in susceptible individu-
als. Rather, it implies that individuals who are genetically
susceptible to developing kidney disease need to pay even
closer attention to modifiable risk factors.
Familial clustering of disparate causes of ESRD has
been reported by several groups, including families with
members having nephropathy associated with types 1
and 2 diabetes mellitus, hypertension, chronic glomeru-
lonephritis, systemic lupus erythematosus, and human
immunodeficiency virus (HIV) infection [6,12–16]. In
addition, a case-control study by Lei et al concluded that
familial clustering of renal disease occurred in excess of
that which could be accounted for by the clustering of
hypertension and diabetes mellitus within families [17].
Additionally, family history of hypertension or diabetes
was not significantly associated with ESRD, once adjust-
ment was made for personal history of these conditions.
This suggests that additional factors beyond the presence
of a permissive environment are necessary in order for
nephropathy to develop.
Familial clustering occurs to a greater extent in mem-
bers with early onset of nephropathy [8]. This has been
observed in African Americans with HIV-associated
nephropathy [14] and in Polish subjects with various eti-
ologies of ESRD [18]. In this Polish population, early
onset of ESRD (onset prior to age 45 vs. onset after age
65) was associated with a two-fold greater likelihood of
a positive family history. A report from Lebanon found
that 26% of 925 hemodialysis patients were offspring
of consanguineous marriages [19]. Thirty-five percent of
subjects from consanguineous marriages had early on-
set of ESRD (before age 30) compared with 21% of
non-consanguineous offspring (P < 0.01). In this report,
6.2% of subjects had polycystic kidney disease, and 47%
had undiagnosed etiologies of renal failure. However, the
theme of these reports from diverse populations supports
the concept that a genetic contribution to the familial
clustering of renal disease exists.
In 324 patients from 80 families with autosomal-
dominant polycystic kidney disease, the location of the
PKD1 gene mutation correlated with both severity of re-
nal disease and age at onset of ESRD [20]. Patients with
PKD1 mutations in the 5′ region had a median age at
ESRD onset of 53 years, while those with mutations in
the 3′ region had median age at onset of 56 years (P =
0.025). Those individuals with 5′ mutations had only an
18.9% incidence of renal survival at age 60, compared
with 39.7% of those with 3′ mutations. All subjects (N =
6) with onset of ESRD prior to age 35 had 5′ muta-
tions. These findings were not replicated in a study in
461 patients from 74 families with PKD2 mutations [21].
In PKD2 families, the location of the mutation did not
appear to impact age at onset of ESRD.
THE SEARCH FOR GENES ASSOCIATED WITH
NEPHROPATHY
In the U.S., more than 35% of prevalent ESRD pa-
tients have diabetic nephropathy. It is anticipated that
as many as 58% will have diabetes-associated ESRD in
2030 [1]. Due to the substantial health care burden of di-
abetic ESRD and the marked familial aggregation, this
population has been targeted for genetic analysis.
A major susceptibility locus for type 1 diabetic
nephropathy was identified on chromosome 3q using dis-
cordant sib-pair analysis. Sixty-six Caucasian American
siblings concordant for type 1 diabetes mellitus, but dis-
cordant for renal disease, were evaluated [22]. This puta-
tive diabetic nephropathy susceptibility locus lies within
a 20-cM region surrounding the angiotensin II type 1 re-
ceptor gene (ATI). Confirmation of linkage in type 1 di-
abetic nephropathy was provided in ethnic Russians on
chromosome 3q21-25, in the vicinity of the ATI gene [23].
We performed a genome-wide scan in 206 sibling
pairs concordant for type 2 diabetic nephropathy from
166 African American families. Ordered subsets analy-
sis (OSA) and nonparametric linkage (NPL) regression
analysis demonstrated consistent evidence for linkage on
chromosomes 3q, 10q, and 18q [24]. The 3q peak was in
the same region as the type 1 diabetic nephropathy locus
reported by Moczulski et al [22] and Savost’ianov et al
[23].
In Caucasian Americans with type 2 diabetes melli-
tus (662 subjects from 310 families, with 422 diabetes-
concordant sib pairs), the estimated heritability (h2) of
glomerular filtration rate (GFR) was 0.75 ± 0.10 (P <
0.0001) after adjustment for age, sex, mean arterial pres-
sure, medications, and hemoglobin A1c [25]. Heritability
of urine albumin-creatinine ratio (ACR) was 0.46 ± 0.12
(P < 0.0001) after similar adjustment. These covariates
were estimated to account for only 2% of the total pheno-
typic variance in log GFR and 9% of the total phenotypic
variance in ACR.
In an attempt to assess for linkage between markers
on human chromosome 10 [in the region of the human
homologue of the rodent renal failure 1 gene (Rf -1)] and
ESRD, we performed a linkage analysis in 356 African
American sib-pairs concordant for ESRD (with etiolo-
gies including hypertension, diabetes mellitus, glomeru-
lonephritis, or unknown cause of ESRD) [26]. In African
American individuals with early onset, nondiabetic eti-
ologies of ESRD, suggestive evidence for linkage was
identified on chromosome 10p, near marker D10S1435,
and this has been confirmed in diabetic families as
well [27]. Variation in creatinine clearance in European
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Americans with essential hypertension has also been
linked to markers on chromosome 10 [28].
The Family Investigation of Nephropathy and Diabetes
(FIND) is a multicenter, National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK)-sponsored
consortium which is currently performing family-based
linkage analyses on diabetic sibs both concordant (af-
fected sib pairs, ASPs) and discordant (discordant sib
pairs, DSPs) for nephropathy [29]. Recruitment of nearly
10,000 subjects has been anticipated by late 2004. In
addition to family-based linkage analyses in African
American, American Indian, Hispanic American, and
European American sibs, mapping by admixture linkage
disequilibrium (MALD) analyses are being performed in
unrelated African American and Hispanic American di-
abetic nephropathy cases and diabetic non-nephropathy
controls. The Genetics of Kidney Disease in Diabetes
(GOKIND) study is in the process of recruiting a planned
total of 1100 trios of type 1 diabetic individuals (with and
without nephropathy) and their parents for transmission
disequilibrium testing [30]. Both of these large-scale stud-
ies have the ultimate goal of identifying the causative
genes linked to diabetic nephropathy.
POPULATION-BASED SCREENING STUDIES
More than 35,000 incident dialysis patients were en-
rolled in the U.S. ESRD Network 6 “Family History of
ESRD” registry. A pilot study from our institution at-
tempted to contact first-degree relatives of a random sam-
ple of ESRD index cases from this registry [31]. Relatives
were encouraged to visit their primary care physicians for
renal-related health care screening. Among 88 relatives, a
significant number were found to have risk factors for kid-
ney disease, although none had renal insufficiency. Nearly
22% of relatives had uncontrolled hypertension, 18.1%
elevated fasting serum glucose, and 26.2% albuminuria.
The second phase of this study will involve a health-fair
type screening of a larger number of first-degree rela-
tives from index cases at multiple dialysis units in North
Carolina.
The National Kidney Foundation’s Kidney Early Eval-
uation Program (KEEP) has conducted community
screening of high-risk individuals throughout the United
States since 1997 [32, 33]. High-risk individuals include
those with a personal history of diabetes or hypertension,
and those with a family history of diabetes, hypertension,
or chronic kidney disease in a first-degree relative. To
date, over 11,000 subjects have undergone screening [33].
During the first year of screening in 889 subjects, 420 had
laboratory abnormalities suggestive of nephropathy (114
with elevated serum creatinine concentration, 170 with
microalbuminuria, 137 with pyuria, and 165 with hema-
turia) [32]. In both the “Family History of ESRD” and
KEEP screening studies, many individuals with evidence
of either nephropathy or risk factors for nephropathy
were previously unaware of their status.
The largest such screening study reported to date has
been carried out by the National Kidney Foundation of
Singapore, enrolling 213,873 adults of Chinese, Malay,
and Asian Indian descent [34]. In contrast to the two U.S.
screening studies, the Singapore study enrolled healthy
adults at their work sites, rather than targeting high-risk
individuals. Complete data regarding family history of
kidney disease was obtained for 158,576 subjects, 5893 of
whom (3.7%) reported a positive history. It is not clear
what percentage of subjects had relatives with ESRD, or
what percentage had first-degree relatives (as opposed to
distant relatives) with nephropathy. Multivariate analysis
revealed a highly significant association between family
history of kidney disease and personal history of pro-
teinuria (odds ratio 2.0, P < 0.001). This study contains
valuable information, as most of the prior epidemiologic
data regarding family history of nephropathy have been
reported in populations of European or African descent.
CONCLUSION
Considerable evidence supports family history of re-
nal disease as one of the most important risk factors as-
sociated with development of nephropathy. The familial
clustering of ESRD supports a genetic contribution to the
pathogenesis of chronic kidney failure. Genomic analyses
and family-based screening studies are underway to more
clearly define the role of genomic factors in nephropathy
susceptibility. Identification of causative genes may al-
low the development of novel therapies targeted at gene
products. Hopefully, these therapies will delay or prevent
progression of chronic kidney disease and curb the world-
wide epidemic of ESRD.
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